Transthyretin amyloidosis has no known treatment (ATTR amyloidosis). The Transthyretin amyloidosis treatment is a two-step process that includes treating the underlying cause as well as managing symptoms. Transthyretin amyloidosis is a life-threatening systemic disorder characterised by the deposition of transthyretin (TTR) fibrils in organs and tissue. It's an uncommon condition marked by the abnormal formation of amyloid deposits in the body's organs and tissues, which are made up of misfolded transthyretin protein. Wild type transthyretin amyloidosis and inherited transthyretin amyloidosis are two kinds of transthyretin amyloidosis.
Hereditary transthyretin amyloidosis is classified into three types: cardiomyopathy, polyneuropathy, and mixed type. transthyretin amyloidosis treatment includes disease modification with USFDA-approved medicines such as inotersen, tafamidis, and patisiran. These medications decrease the advancement of amyloid illness, but they are not a cure. Tafamidis and inotersen are approved for the treatment of polyneuropathy caused by hereditary transthyretin-related amyloidosis (hATTR) in adults, while inotersen and patisiran are approved for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Read More: https://bit.ly/3G0FoRD
